We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+9.96%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$25.2B
AUM Growth
-$335M
(-1.3%)
Cap. Flow
-$2.05B
Cap. Flow
% of AUM
-8.13%
Top 10 Holdings %
Top 10 Hldgs %
26.87%
Holding
1,147
New
127
Increased
298
Reduced
504
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$160M |
| 2 |
Masco
MAS
|
+$134M |
| 3 |
Lam Research
LRCX
|
+$112M |
| 4 |
Coupang
CPNG
|
+$101M |
| 5 |
Nu Holdings
NU
|
+$98.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Vernova
GEV
|
+$205M |
| 2 |
Lennox International
LII
|
+$191M |
| 3 |
NVIDIA
NVDA
|
+$169M |
| 4 |
Tractor Supply
TSCO
|
+$157M |
| 5 |
Apple
AAPL
|
+$151M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.69% |
| 2 | Consumer Discretionary | 12.85% |
| 3 | Industrials | 12.71% |
| 4 | Financials | 12.68% |
| 5 | Healthcare | 9.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Insperity
NSP
$1.98B
| $42.3M | 0.17% |
860,020
+244,350
| +40% | +$13.4M |
|
127
KBR
KBR
$4.76B
| $42M | 0.17% |
888,499
-7,038
| -0.8% | -$341K |
|
128
Argan
AGX
$7.26B
| $41.3M | 0.16% |
153,115
+116,657
| +320% | +$26.7M |
|
129
ExxonMobil
XOM
$633B
| $41.1M | 0.16% |
364,949
+6,820
| +2% | +$758K |
|
130
Sempra
SRE
$59.8B
| $41.1M | 0.16% |
456,969
-68,095
| -13% | -$5.51M |
|
131
Winmark
WINA
$1.23B
| $40.5M | 0.16% |
81,433
+68,603
| +535% | +$29.5M |
|
132
Hanover Insurance
THG
$7.8B
| $39.6M | 0.16% |
217,810
-27,672
| -11% | -$4.74M |
|
133
EOG Resources
EOG
$74.6B
| $39.4M | 0.16% |
350,966
-366,983
| -51% | -$43.8M |
|
134
Primoris Services
PRIM
$4.39B
| $39.3M | 0.16% |
286,420
-61,288
| -18% | -$6.58M |
|
135
Tetra Tech
TTEK
$8.66B
| $39.2M | 0.16% |
1,174,227
-105,414
| -8% | -$3.83M |
|
136
TechnipFMC
FTI
$29B
| $39M | 0.15% |
987,489
-635,777
| -39% | -$23.3M |
|
137
Cullen/Frost Bankers
CFR
$10.4B
| $38.1M | 0.15% |
300,715
-27,502
| -8% | -$3.57M |
|
138
First American
FAF
$8.02B
| $37.9M | 0.15% |
589,349
-55,280
| -9% | -$3.49M |
|
139
Cirrus Logic
CRUS
$6.84B
| $37.8M | 0.15% |
301,378
+3,517
| +1% | +$392K |
|
140
Moderna
MRNA
$22B
| $37.5M | 0.15% |
1,449,931
+103,981
| +8% | +$2.9M |
|
141
Cintas
CTAS
$86.7B
| $37M | 0.15% |
180,419
-147,175
| -45% | -$31.4M |
|
142
ArcBest
ARCB
$3.33B
| $36.4M | 0.14% |
520,886
+24,102
| +5% | +$1.81M |
|
143
RingCentral
RNG
$4.74B
| $35.8M | 0.14% |
1,261,955
-400,925
| -24% | -$11.7M |
|
144
Reliance Steel & Aluminium
RS
$21.1B
| $35.2M | 0.14% |
125,490
-52,668
| -30% | -$15.8M |
|
145
10x Genomics
TXG
$5.99B
| $34.5M | 0.14% |
2,947,989
+550,250
| +23% | +$7.17M |
|
146
Huntsman Corp
HUN
$2.03B
| $33.9M | 0.13% |
3,779,622
+769,058
| +26% | +$8.08M |
|
147
Powell Industries
POWL
$7.43B
| $33.6M | 0.13% |
331,068
-25,029
| -7% | -$2.12M |
|
148
Indivior Pharmaceuticals
INDV
$4.76B
| $33.5M | 0.13% |
+1,389,289
| New | +$29.1M |
|
149
Robert Half
RHI
$4.08B
| $33.3M | 0.13% |
979,615
-123,151
| -11% | -$4.62M |
|
150
Mercury Insurance
MCY
$6.09B
| $33.1M | 0.13% |
390,810
+13,701
| +4% | +$1.01M |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q3 2025 Portfolio in Review
As of Q3 2025, Jacobs Levy Equity Management held 1,147 positions worth $25.2B, down 1.3% from $25.5B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Jacobs Levy Equity Management withdrew a net $2.05B in Q3 2025, closing 194 positions and reducing 504 holdings. Its most notable exit was Progressive, an estimated $66.7M position sold in full.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Jacobs Levy Equity Management opened a new position in Bank of America worth $45M.
- Jacobs Levy Equity Management's largest Q3 2025 buy was Bank of America: 873,228 shares worth $45M.
- Jacobs Levy Equity Management added most to Alnylam Pharmaceuticals in Q3 2025, an estimated $160M increase.
- Jacobs Levy Equity Management's biggest Q3 2025 reduction was GE Vernova, cutting an estimated $205M.
- Jacobs Levy Equity Management fully exited Progressive in Q3 2025, selling an estimated $66.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 27% of its $25.2B portfolio in Q3 2025.
- Jacobs Levy Equity Management opened 127 new positions and closed 194 in Q3 2025.
- Jacobs Levy Equity Management's portfolio value fell 1.3% quarter-over-quarter to $25.2B.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.